Head of R&D, Anders Ullman, leaves Biovitrum Anders Ullman, Head of R&D, will leave Biovitrum on December 31, 2006, for a position as Head of R&D at the European pharmaceutical company Nycomed. Biovitrum has during 2005 and 2006, accomplished significant changes in the organizational structure within R&D and of the project portfolio. Biovitrum is now, after completed changes, a stable biopharma company with a cost efficient and flexible R&D-organisation and with a broad and balanced project portfolio with several projects in, or near, clinic development phase. Biovitrum's CEO, Mats Pettersson comments: "Anders Ullman has brought to Biovitrum valuable experience from change management within R&D and we wish him all the luck for the future. Biovitrum now enters into a new phase with focus on managing and commercially develop the portfolio forward." For additional information, please contact: Biovitrum AB (publ) Mats Pettersson, CEO +46 8 697 23 27 [email protected] Anna Karin Källén, Vice President, Corporate Communications +46 8 697 20 85, cell phone: +46 734 33 20 85 [email protected] About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has approximately revenues of USD 119 million and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://wpy.waymaker.net/client/waymaker1/f.aspx?id=332398&fn=wkr0001.pdf
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.